Camptothecin-based dendrimersomes for gene delivery and redox-responsive drug delivery to cancer cells
- 15 October 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 11 (42) , 20058-20071
Abstract
Combination therapy involving chemotherapeutic drugs and genes is emerging as a promising strategy to provide a synergistic therapeutic effect, to overcome drug resistance while reducing the severe side effects associated with conventional chemotherapeutic drugs. However, the lack of nanomedicines able to simultaneously carry anti-cancer drugs and nucleic acids limits the application of this therapeutic strategy. To overcome this issue, we proposed to synthesize a pro-drug dendrimer by conjugating the PEGylated, positively charged generation 3-diaminobutyric polypropylenimine dendrimer to the anti-cancer drug camptothecin with a redox-sensitive disulphide linkage, and evaluate its efficacy to co-deliver the complexed DNA and camptothecin to cancer cells. This PEGylated pro-drug dendrimer was found to spontaneously self-assemble into cationic (∼3–5 mV) vesicles at pH 7.4, at a critical aggregation concentration of about 200 μg mL−1. These vesicles (dendrimersomes) became smaller (150–200 nm) with increasing dendrimer concentration and remained stable over 7 days. They were able to release about 70% of the conjugated camptothecin in presence of 50 mM glutathione (equivalent to the intracellular environment of tumor tissue). They could also condense more than 85% of the DNA at dendrimer : DNA weight ratios of 5 : 1 and higher. DNA condensation occurred instantly and was found to be stable for at least 24 h. This led to an enhanced cellular uptake of DNA (by up to 1.6-fold) and increased gene transfection (by up to 2.4-fold) in prostate cancer cells in comparison with the unmodified dendrimer. These novel dendrimersomes are therefore promising for single carrier-based combination cancer therapy.Keywords
Funding Information
- Worldwide Cancer Research (16-1303)
- Vivensa Foundation (R463/0216)
This publication has 47 references indexed in Scilit:
- Effective Gene Delivery Using Stimulus-Responsive Catiomer Designed with Redox-Sensitive Disulfide and Acid-Labile Imine LinkersBiomacromolecules, 2012
- Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanismChemical Communications, 2011
- PAMAM-Camptothecin Conjugate Inhibits Proliferation and Induces Nuclear Fragmentation in Colorectal Carcinoma CellsPharmaceutical Research, 2010
- Charge‐Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug DeliveryAdvanced Functional Materials, 2009
- Self-assembly of pH-responsive fluorinated dendrimer-based particulates for drug delivery and noninvasive imagingBiomaterials, 2009
- Synthesis and In Vivo Antitumor Efficacy of PEGylated Poly(l-lysine) Dendrimer−Camptothecin ConjugatesMolecular Pharmaceutics, 2009
- Systematic Investigation of Polyamidoamine Dendrimers Surface-Modified with Poly(ethylene glycol) for Drug Delivery Applications: Synthesis, Characterization, and Evaluation of CytotoxicityBioconjugate Chemistry, 2008
- In Vitro Cytotoxicity and in Vivo Distribution after Direct Delivery of PEG−Camptothecin Conjugates to the Rat BrainBioconjugate Chemistry, 2004
- Synthesis of a Macromolecular Camptothecin Conjugate with Dual Phase Drug ReleaseMolecular Pharmaceutics, 2004
- Fluorescence from Azobenzene Functionalized Poly(propylene imine) Dendrimers in Self-Assembled Supramolecular StructuresJournal of the American Chemical Society, 2000